PPARA and fatty liver disease: Bujanda et al. (2008) reported that in rats with fatty liver infection (non-alcoholic) and found that it inhibited de novo lipogenesis of adipocytes, adipogenic differentiation, and reduced hepatic steatosis. Another report by Jiang et al. (2012) showed that Resveratol exhibited effective activity against HCV core protein-stimulated hepatic steatosis by enhancing the PPAR-a levels, which was inhibited through the HCV core protein, in vivo and in vitro.